As part of its annual Industry Issues Conference in December, Drug Store News hosted the Chronic Care and Retail Health Roundtable, expanding the program for the first time in its 15 year-existence beyond the diabetes management.
Health Canada announced earlier this week that it had revised the Federal Prescription Drug use and reclassified naloxone as a Schedule II drug, making it available without a prescription.
Increasingly, states are looking to address the prescription painkiller problem with as many as 375 proposals coursing through state legislatures that would regulated pain clinics and prescribing painkillers, The New York Times reported Friday. "The states are going to lead on this one because Big Pharma has too much power," Vermont Gov. Peter Shumlin, Democrat, told The New York Times. The New York Times added: "The pace of [legislative] activity in states has grown so intense that experts are having difficulty keeping track." (The New York Times)
In December, DSN hosted its 17th annual Industry Issues Summit. A record crowd of some 300 supplier and retailer executives were on hand to see seven top merchants from leading chains and special guest moderator Dan Mack, managing director, Elevation Forum, discuss how retailers and suppliers could build better, higher-trusting partnerships, based on authenticity and creating deeper value. What follows is the complete transcript from the December 3rd event.
Walgreens will install safe medication disposal kiosks in more than 500 drug stores in 39 states and make naloxon available without a prescription at its pharmacies in 35 states.
The Food and Drug Administration has approved Narcan, a nasal spray dose of naloxone, which is typically administered via injection.
HealthDay is reporting that researchers fromt the University of Michigan’s Survey Research Center have found that a person’s use of narcotic painkillers as a teen raises their risk of abuse as an adult by 33%. “Most likely, the initial experience of pain relief is pleasurable and a safe initial experience may reduce perceived danger,” the study’s author Richard Miech said. “A pleasurable and safe initial experience with a drug is a central factor in theories of who goes on to misuse drugs.” (HealthDay)
Using 2013 data from state prescription drug monitoring programs from eight states, the CDC found that prescribing practices between states vary drastically.
With an estimated 60 million people in the United States experiencing heartburn at least once a month, and more than 15 million suffering from it daily, products to treat the condition have become more sophisticated, and the battle for supremacy in the $2.18 billion-a-year antacid tablets market has grown more heated.